Familial Amyloid Neuropathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Familial Amyloid Neuropathies Pipeline Drugs Market Report Overview

Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues. Symptoms include numbness, tingling, pins, and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness, and fainting.

The Familial Amyloid Neuropathies pipeline drugs market research report provides comprehensive information on the therapeutics under development for Familial Amyloid Neuropathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects.

Familial Amyloid Neuropathies Pipeline Drugs Market Segmentation by Targets

Some of the key targets of the Familial Amyloid Neuropathies pipeline drugs market are Transthyretin, Alpha Synuclein, Amyloid Beta A4 Protein, and Microtubule Associated Protein Tau. Transthyretin leads this segment of the Familial Amyloid Neuropathies pipeline drugs market.

Familial Amyloid Neuropathies Pipeline Drugs Market Analysis, by Targets

For more target insights on Familial Amyloid Neuropathies pipeline drugs market, download a free report sample

Familial Amyloid Neuropathies Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Familial Amyloid Neuropathies pipeline drugs market are Transthyretin Inhibitor, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, and Microtubule Associated Protein Tau Inhibitor. Transthyretin Inhibitor leads the Familial Amyloid Neuropathies pipeline drugs market in terms of MoA.

Familial Amyloid Neuropathies Pipeline Drugs Market Analysis, by Mechanisms of Action

For more MoA insights into the Familial Amyloid Neuropathies pipeline drugs market, download a free report sample

Familial Amyloid Neuropathies Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Familial Amyloid Neuropathies pipeline drugs market are intravenous, subcutaneous, parenteral, and oral. Intravenous leads the Familial Amyloid Neuropathies pipeline drugs market in terms of RoA. 

Familial Amyloid Neuropathies Pipeline Drugs Market Analysis, by Routes of Administration

For more RoA insights into the Familial Amyloid Neuropathies pipeline drugs market, download a free report sample

Familial Amyloid Neuropathies Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Familial Amyloid Neuropathies pipeline drugs market are small molecule, antisense oligonucleotide, antisense RNAi oligonucleotide, gene therapy, antibody, fusion protein, and monoclonal antibody. Small molecule leads the Familial Amyloid Neuropathies pipeline drugs market in terms of molecule types.

Familial Amyloid Neuropathies Pipeline Drugs Market Analysis, by Molecule Types

For more molecule-type insights into the Familial Amyloid Neuropathies pipeline drugs market, download a free report sample

Familial Amyloid Neuropathies Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Familial Amyloid Neuropathies pipeline drugs market are Akcea Therapeutics Inc, Alnylam Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, ADRx Inc, BSIM Therapeutics SA, Corino Therapeutics Inc, Novo Nordisk AS, and Proclara Biosciences Inc. Akcea Therapeutics Inc, Alnylam Pharmaceuticals Inc, and Regeneron Pharmaceuticals Inc have the highest number of Familial Amyloid Neuropathies drugs under development in 2022.

Familial Amyloid Neuropathies Pipeline Drugs Market Analysis, by Companies

To know more about the leading Familial Amyloid Neuropathies pipeline drugs market players, download a free report sample

Familial Amyloid Neuropathies Pipeline Drugs Market Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Amyloid Neuropathies.
• The pipeline guide reviews pipeline therapeutics for Familial Amyloid Neuropathies by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Familial Amyloid Neuropathies therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Familial Amyloid Neuropathies therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Familial Amyloid Neuropathies

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Familial Amyloid Neuropathies.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the Familial Amyloid Neuropathies pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.